Welcome to LookChem.com Sign In|Join Free
  • or
tert-butyl (3S)-3-{benzyl[(1R)-1-phenylethyl]amino}-3-(6-methoxypyridin-3-yl)propanoate is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

339555-40-7

Post Buying Request

339555-40-7 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

339555-40-7 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 339555-40-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,3,9,5,5 and 5 respectively; the second part has 2 digits, 4 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 339555-40:
(8*3)+(7*3)+(6*9)+(5*5)+(4*5)+(3*5)+(2*4)+(1*0)=167
167 % 10 = 7
So 339555-40-7 is a valid CAS Registry Number.

339555-40-7Relevant academic research and scientific papers

An efficient synthesis of an alphavbeta3 antagonist.

Yasuda, Nobuyoshi,Hsiao,Jensen, Mark S,Rivera, Nelo R,Yang, Chunhua,Wells, Kenneth M,Yau, James,Palucki, Michael,Tan, Lushi,Dormer, Peter G,Volante, Ralph P,Hughes, David L,Reider, Paul J

, p. 1959 - 1966 (2004)

A practical preparation of an alpha(v)beta(3) antagonist is reported. The antagonist consists of three key components, a tetrahydronaphthyridine moiety, a beta-alanine moiety, and a central imidazolidone moiety. The tetrahydronaphthyridine component was p

COMPOSITION AND METHODS FOR TREATING CHRONIC KIDNEY DISEASE

-

Page/Page column 23, (2016/10/11)

This invention relates to the treatment of chronic kidney disease, including diabetic nephropathy, focal segmental glomerulosclerosis (FSGS), nephrotic syndrome, non-diabetic chronic kidney disease, renal fibrosis or acute kidney injury by the administrat

COMPOSITIONS AND METHODS FOR TREATING CANCER

-

, (2012/12/13)

The instant invention provides a method of treating a cancer selected from the group consisting of non-small cell lung cancer and breast cancer with an mTOR inhibitor and an αvβ3 integrin antagonist, wherein the mTOR inhibitor is ridaforolimus, everolimus, temsirolimus or a combination thereof.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 339555-40-7